Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
Lung Cancer Update
00:00
The Impact of Immune Therapy on Cancer
NIBU was the second class of novel immunotherapy ethics after EP LEMOMA. It's really changed what we're able to do to help most patients, says Dr. Luis Gómez. With that, and we'll go through some of the data later today, there's a 20% chance that someone's going to be doing okay in five years.
Transcript
Play full episode
